Oxford BioMedicaLSE:OXB -0.16%68 Gross Margin % is 35.93% as of Dec. 2025, which is 28% below its 10-year median of 49.81. GuruFocus rates LSE:OXB with a GF Score™ of 68/100 and a GF Value™ of £5.36 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 735 Biotechnology companies, Oxford BioMedica ranks worse than 69.39% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Oxford BioMedica had a gross margin of 35.93% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Oxford BioMedica Gross Margin % Related Terms
Oxford BioMedica Gross Margin % Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OXB vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Oxford BioMedica's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Oxford BioMedica (LSE:OXB) has a Gross Margin % of 35.93% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Oxford BioMedica and its competitors. This is 28% below median its historical median of 49.81. Over the past decade, Oxford BioMedica's Gross Margin % has ranged from 39.10 to 57.87. According to the industry distribution chart, Oxford BioMedica ranks #510 out of 735 companies in the Biotechnology industry, placing it in the top 69.4%.
Is Oxford BioMedica's Gross Margin % too high?
Oxford BioMedica's current Gross Margin % of 35.93% is 28% below median its 10-year median of 49.81. Over the past 10 years, this metric has ranged from a low of 39.10 to a high of 57.87. The Biotechnology industry median Gross Margin % is 60.90. Oxford BioMedica's value of 35.93% is 41% below this industry median. Based on the distribution chart, Oxford BioMedica ranks #510 out of 735 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #510 out of 735 companies for Gross Margin %. This places Oxford BioMedica in the lower half of its industry. The industry median Gross Margin % is 60.90. Oxford BioMedica's value of 35.93% is 41% below this benchmark. Historically, Oxford BioMedica's own Gross Margin % has ranged from 39.10 to 57.87 over the past decade. While the company's 10-year median is 49.81 vs. the industry median of 60.90, Oxford BioMedica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioMedica's current Gross Margin % of 35.93% is 41% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Gross Margin % is 35.93%, which is 28% below median its own 10-year median of 49.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.36, compared to a current price of £6.33 — trading 18.1% above its estimated fair value. The current Gross Margin % is 35.93%, which is 28% below median its 10-year median of 49.81 and 41% below the Biotechnology industry median of 60.90. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current Gross Margin % is 35.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of £6.33 is trading 18.1% above its estimated GF Value™ of £5.36.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for LSE:OXB:
Gross Margin %: 35.93% (28% below median its 10-year median of 49.81)
GF Value™: £5.36 vs. price of £6.33 (18.1% above fair value)
Industry Position: 41% below the Biotechnology median (#510 of 735)
No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score
Get the complete analysis for LSE:OXB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OXB has been successfully added to your 
